Overview Fundamentals API Earnings EOD API Sample Code Pricing

Editas Medicine Inc (EDIT NASDAQ) stock market data APIs

$5.57 0.23(4.3%) as of July 24, 2024
Price chart is built with Anychart

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc Financial Data Overview

459 M
82 238 K
69 407 K
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'EDIT',
Type: 'Common Stock',
Name: 'Editas Medicine Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG005MX5GZ2',
CIK: '1650664',
EmployerIdNumber: '46-4097528',
FiscalYearEnd: 'December',
IPODate: '2016-02-03',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,

Editas Medicine Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 69 407 K
  • EBITDA -179 282 000
  • Earnings Per Share -2.07
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Editas Medicine Inc Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast -0.66

Get Editas Medicine Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?